155 related articles for article (PubMed ID: 35168148)
1. Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer.
Smithson M; Irwin RK; Williams G; McLeod MC; Choi EK; Ganguly A; Pepple A; Cho CS; Willey CD; Leopold J; Hardiman KM
Neoplasia; 2022 Mar; 25():53-61. PubMed ID: 35168148
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer.
Gordhandas SB; Manning-Geist B; Henson C; Iyer G; Gardner GJ; Sonoda Y; Moore KN; Aghajanian C; Chui MH; Grisham RN
Sci Rep; 2022 Jan; 12(1):974. PubMed ID: 35046420
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
Zenke FT; Zimmermann A; Sirrenberg C; Dahmen H; Kirkin V; Pehl U; Grombacher T; Wilm C; Fuchss T; Amendt C; Vassilev LT; Blaukat A
Mol Cancer Ther; 2020 May; 19(5):1091-1101. PubMed ID: 32220971
[TBL] [Abstract][Full Text] [Related]
4. A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.
Romesser PB; Capdevila J; Garcia-Carbonero R; Philip T; Fernandez Martos C; Tuli R; Rodriguez-Gutierrez A; Kuipers M; Becker A; Coenen-Stass A; Sarholz B; You X; Miller ED
Clin Cancer Res; 2024 Feb; 30(4):695-702. PubMed ID: 38051750
[TBL] [Abstract][Full Text] [Related]
5. DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
Haines E; Nishida Y; Carr MI; Montoya RH; Ostermann LB; Zhang W; Zenke FT; Blaukat A; Andreeff M; Vassilev LT
Sci Rep; 2021 Jun; 11(1):12148. PubMed ID: 34108527
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors.
Samuels M; Falkenius J; Bar-Ad V; Dunst J; van Triest B; Yachnin J; Rodriguez-Gutierrez A; Kuipers M; You X; Sarholz B; Locatelli G; Becker A; Troost EGC
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):743-756. PubMed ID: 37751793
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Poor Response to Neoadjuvant Chemoradiation in Patients With Rectal Cancer Using a DNA Repair Deregulation Score: Picking the Losers Instead of the Winners.
Jimenez L; Perez RO; São Julião GP; Vailati BB; Fernandez LM; Gama-Rodrigues J; Habr-Gama A; DeVecchio J; Kalady MF; Camargo AA
Dis Colon Rectum; 2020 Mar; 63(3):300-309. PubMed ID: 31842156
[TBL] [Abstract][Full Text] [Related]
8. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
Wise HC; Iyer GV; Moore K; Temkin SM; Gordon S; Aghajanian C; Grisham RN
Sci Rep; 2019 Dec; 9(1):18882. PubMed ID: 31827119
[TBL] [Abstract][Full Text] [Related]
9. DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy.
Carr MI; Chiu LY; Guo Y; Xu C; Lazorchak AS; Yu H; Qin G; Qi J; Marelli B; Lan Y; Sun Q; Czauderna F; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Res; 2022 Apr; 20(4):568-582. PubMed ID: 34980594
[TBL] [Abstract][Full Text] [Related]
10. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
11. Metformin as an Alternative Radiosensitizing Agent to 5-Fluorouracil During Neoadjuvant Treatment for Rectal Cancer.
Fernandes JM; Jandrey EHF; Koyama FC; Leite KRM; Camargo AA; Costa ÉT; Perez RO; Asprino PF
Dis Colon Rectum; 2020 Jul; 63(7):918-926. PubMed ID: 32229782
[TBL] [Abstract][Full Text] [Related]
12. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.
Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM
J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
Svoboda M; Sana J; Fabian P; Kocakova I; Gombosova J; Nekvindova J; Radova L; Vyzula R; Slaby O
Radiat Oncol; 2012 Nov; 7():195. PubMed ID: 23167930
[TBL] [Abstract][Full Text] [Related]
14. Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer.
Koyama FC; Lopes Ramos CM; Ledesma F; Alves VAF; Fernandes JM; Vailati BB; São Julião GP; Habr-Gama A; Gama-Rodrigues J; Perez RO; Camargo AA
Br J Surg; 2018 Jan; 105(2):e192-e203. PubMed ID: 29341150
[TBL] [Abstract][Full Text] [Related]
15. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814.
Sun Q; Guo Y; Liu X; Czauderna F; Carr MI; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Res; 2019 Dec; 17(12):2457-2468. PubMed ID: 31551253
[TBL] [Abstract][Full Text] [Related]
17. DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer.
Wang M; Chen S; Wei Y; Wei X
Acta Pharm Sin B; 2021 Dec; 11(12):3935-3949. PubMed ID: 35024317
[TBL] [Abstract][Full Text] [Related]
18. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
Martinez-Useros J; Moreno I; Fernandez-Aceñero MJ; Rodriguez-Remirez M; Borrero-Palacios A; Cebrian A; Gomez Del Pulgar T; Del Puerto-Nevado L; Li W; Puime-Otin A; Perez N; Soengas MS; Garcia-Foncillas J
BMC Cancer; 2018 Feb; 18(1):144. PubMed ID: 29409457
[TBL] [Abstract][Full Text] [Related]
19. A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.
van Bussel MTJ; Awada A; de Jonge MJA; Mau-Sørensen M; Nielsen D; Schöffski P; Verheul HMW; Sarholz B; Berghoff K; El Bawab S; Kuipers M; Damstrup L; Diaz-Padilla I; Schellens JHM
Br J Cancer; 2021 Feb; 124(4):728-735. PubMed ID: 33230210
[TBL] [Abstract][Full Text] [Related]
20. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
[Next] [New Search]